A systematic review found that ketamine produced a 48% response rate in treatment-resistant depression — nearly 10 times the placebo rate. But a significant risk of triggering mania means this is far from a simple solution.

For people with bipolar disorder who don’t respond to standard treatments, the depressive episodes can be devastating — lasting months, destroying quality of life, and carrying serious suicide risk.

A systematic review published in 2023 by Fancy et al. analyzed data from 203 patients across multiple studies and found that ketamine produced a 48% response rate in treatment-resistant bipolar depression, compared to just 5% for placebo.

Those numbers are striking. A nearly tenfold difference between drug and placebo is unusual in psychiatric research, where effect sizes tend to be modest.

Ketamine also works fast — often within hours or days rather than the weeks required for traditional antidepressants. For someone in the depths of a bipolar depressive episode, that speed could be life-changing. But the full picture is more complicated.

The most significant concern: a 28.9% manic switch rate during maintenance ketamine treatment. That means roughly one in three patients who continued ketamine therapy experienced a shift into mania or hypomania.

For anyone who has experienced a manic episode, this is not a minor side effect — it can mean hospitalization, destroyed relationships, financial ruin, and in severe cases, psychosis. Trading one pole of the illness for the other is not really a treatment success.

It’s also important to understand what ketamine is not in this context. Esketamine (marketed as Spravato), a nasal spray derivative of ketamine, is FDA-approved for treatment-resistant unipolar depression — but it is not FDA-approved for bipolar depression.

Any use of ketamine or esketamine for bipolar depression is off-label and investigational. This distinction matters because bipolar depression responds differently to medications than unipolar depression, and drugs approved for one don’t automatically work — or are safe — for the other.

The review also highlighted significant gaps in the evidence. Most studies were small, with limited follow-up periods. The 48% response rate, while promising, comes from a pooled analysis of heterogeneous studies with varying doses, delivery methods (IV infusion, nasal spray, oral), and definitions of “response.” Larger, longer, well-controlled trials specifically designed for bipolar depression are needed before ketamine can be considered a standard treatment option.

For people considering ketamine, the practical landscape is complicated. Ketamine infusion clinics have proliferated across the United States, many operating with limited psychiatric oversight. A clinic that treats unipolar depression patients may not have the expertise to manage the unique risks ketamine poses for bipolar patients — particularly the manic switch risk, which requires active monitoring and a clear protocol for intervention.

The bottom line: ketamine represents a genuinely promising research direction for treatment-resistant bipolar depression, and the 48% response rate deserves serious attention. But the 28.9% manic switch rate is equally important. Anyone with bipolar disorder considering ketamine should do so only under the supervision of a psychiatrist experienced in bipolar disorder, with full awareness of the risks of mania induction, and ideally within a clinical trial setting where safety monitoring is rigorous.

A note from Robin Miller: I’ve had people in my support group ask about ketamine. It’s usually when they’re deep in a depressive episode and desperate for anything that works faster than six weeks. I get it. Bipolar depression is its own kind of hell, quieter than mania but just as destructive. I remember it well. But when I see the chance of a manic switch, and I think about what my last manic episode cost me, it scares. This is not a treatment I would consider, but I hope it helps people with severe depression.

Sources: Fancy et al. (2023) Systematic Review — PubMed | U.S. Food and Drug Administration

See recent or related posts:
• Study: Psychedelics May Ease Bipolar Depression Without Sparking Mania
• Hospital Visits For Hallucinogens Linked to Sharp Rise in Mania
• FDA Just Approved a New Drug for Bipolar I — Here’s What You Need to Know
• Researchers Testing ‘Ketogenic-Mimicking’ Plan for Treatment of Mania and Depression
• New Book Offers a Metabolic Key to Mania and Mental Health